K-Bio’s potential rises in targeted anticancer therapy
By Son, Hyung-Min | translator Kim, Jung-Ju
24.02.29 06:18:16
가나다라
0
iLeadBMS’s Target Protein Degradation (TPD) candidate shows antitumor activity
PharosiBio’s candidate shows response in preclinical trial for colorectal cancer…’ aims to enter clinical trial stage soon’
The achievements made by the pharmaceutical and bio-industry companies in Korea in developing targeted antitumor therapies are being introduced at academic conferences overseas. iLeadBMS and PharosiBio have announced positive preclinical study results, and have received the green light to enter main clinical trials.
The ESMO Targeted Anticancer Therapies Congress 2024 was held in Paris, France, for 3 days from February 26. The European Society for Medical Oncology, one of the world's three major oncology societies, organizes the congress every year to showcase promising new targets and candidates.
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)